U.S. Supreme Court slaps big pharma for paying generic makers to delay lower cost medications




Ruled 5-3 that agreements between the makers of name-brand and generic drugs to delay the generics' availability can be illegal, an outcome cheered by consumer groups.
CLICK TO VIEW THE SOURCE MATERIAL


Post a comment


You must sign in before you can post comments. If you are experiencing issues with your account please e-mail abuse@unionleader.com.